Switch theme
Sign up to access all valuation multiples
Avita is a single product company. Its RECELL system is an innovative burn treatment device which creates Spray-on Skin from a small skin sample within 30 minutes, thus avoiding or reducing the need for skin grafts. It's approved for the treatment of adult and paediatric patients in the US and an expanded indication for soft-tissue reconstruction. It is currently in roll-out across the approximately 136 US burn centers. Despite having product approval in Australia, Europe, Canada, and China, Avita is not actively marketing in those territories and focussing instead on the US region. However, it is expected to launch in Japan via distribution partner Cosmotec in second-half fiscal 2022. Avita is domiciled, and has its primary listing, in the US.
1992
260
LTM Revenue $78.1M
LTM EBITDA -$39.3M
$167M
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
AVITA Medical has a last 12-month revenue (LTM) of $78.1M and a last 12-month EBITDA of -$39.3M.
In the most recent fiscal year, AVITA Medical achieved revenue of $64.3M and an EBITDA of -$55.3M.
AVITA Medical expects next 12-month revenue of XXX and NTM EBITDA of XXX
See AVITA Medical valuation multiples based on analyst estimates| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue | $78.1M | XXX | $64.3M | XXX | XXX | XXX |
| Gross Profit | $66.2M | XXX | $55.2M | XXX | XXX | XXX |
| Gross Margin | 85% | XXX | 86% | XXX | XXX | XXX |
| EBITDA | -$39.3M | XXX | -$55.3M | XXX | XXX | XXX |
| EBITDA Margin | -50% | XXX | -86% | XXX | XXX | XXX |
| EBIT | -$41.1M | XXX | -$56.6M | XXX | XXX | XXX |
| EBIT Margin | -53% | XXX | -88% | XXX | XXX | XXX |
| Net Profit | -$45.9M | XXX | -$61.8M | XXX | XXX | XXX |
| Net Margin | -59% | XXX | -96% | XXX | XXX | XXX |
| Net Debt | XXX | XXX | $28.2M | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of May 30, 2025, AVITA Medical's stock price is $6.
AVITA Medical has current market cap of $149M, and EV of $167M.
See AVITA Medical trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $167M | $149M | XXX | XXX | XXX | XXX | $-2.27 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Start Free TrialAs of May 30, 2025, AVITA Medical has market cap of $149M and EV of $167M.
AVITA Medical's trades at 2.6x EV/Revenue multiple, and -3.0x EV/EBITDA.
Equity research analysts estimate AVITA Medical's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
AVITA Medical has a P/E ratio of -3.2x.
See valuation multiples for AVITA Medical and 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $149M | XXX | $149M | XXX | XXX | XXX |
| EV (current) | $167M | XXX | $167M | XXX | XXX | XXX |
| EV/Revenue | 2.1x | XXX | 2.6x | XXX | XXX | XXX |
| EV/EBITDA | -4.2x | XXX | -3.0x | XXX | XXX | XXX |
| EV/EBIT | -4.1x | XXX | -2.9x | XXX | XXX | XXX |
| EV/Gross Profit | 2.5x | XXX | n/a | XXX | XXX | XXX |
| P/E | -3.2x | XXX | -2.4x | XXX | XXX | XXX |
| EV/FCF | -4.5x | XXX | -2.9x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Start Free TrialAVITA Medical's last 12 month revenue growth is 45%
AVITA Medical's revenue per employee in the last FY averaged $0.2M, while opex per employee averaged $0.4M for the same period.
AVITA Medical's rule of 40 is -22% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
AVITA Medical's rule of X is 62% (created by Bessemer, rule of X is another metric relevant for SaaS companies only, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
See operational valuation multiples for AVITA Medical and other 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue Growth | 45% | XXX | 45% | XXX | XXX | XXX |
| EBITDA Margin | -50% | XXX | -86% | XXX | XXX | XXX |
| EBITDA Growth | -73% | XXX | n/a | XXX | XXX | XXX |
| Rule of 40 | -22% | XXX | -41% | XXX | XXX | XXX |
| Bessemer Rule of X | XXX | XXX | 62% | XXX | XXX | XXX |
| Revenue per Employee | XXX | XXX | $0.2M | XXX | XXX | XXX |
| Opex per Employee | XXX | XXX | $0.4M | XXX | XXX | XXX |
| S&M Expenses to Revenue | XXX | XXX | 91% | XXX | XXX | XXX |
| G&A Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| R&D Expenses to Revenue | XXX | XXX | 32% | XXX | XXX | XXX |
| Opex to Revenue | XXX | XXX | 174% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Philips | XXX | XXX | XXX | XXX | XXX | XXX |
| Perspective Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| SmartVest | XXX | XXX | XXX | XXX | XXX | XXX |
| InfuSystem | XXX | XXX | XXX | XXX | XXX | XXX |
| Myomo | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
AVITA Medical acquired XXX companies to date.
Last acquisition by AVITA Medical was XXXXXXXX, XXXXX XXXXX XXXXXX . AVITA Medical acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Start Free Trial| When was AVITA Medical founded? | AVITA Medical was founded in 1992. |
| Where is AVITA Medical headquartered? | AVITA Medical is headquartered in United States of America. |
| How many employees does AVITA Medical have? | As of today, AVITA Medical has 260 employees. |
| Who is the CEO of AVITA Medical? | AVITA Medical's CEO is Mr. James M. Corbett. |
| Is AVITA Medical publicy listed? | Yes, AVITA Medical is a public company listed on NAS. |
| What is the stock symbol of AVITA Medical? | AVITA Medical trades under RCEL ticker. |
| When did AVITA Medical go public? | AVITA Medical went public in 2012. |
| Who are competitors of AVITA Medical? | Similar companies to AVITA Medical include e.g. Philips, Perspective Therapeutics, SmartVest, InfuSystem. |
| What is the current market cap of AVITA Medical? | AVITA Medical's current market cap is $149M |
| What is the current revenue of AVITA Medical? | AVITA Medical's last 12 months revenue is $78.1M. |
| What is the current revenue growth of AVITA Medical? | AVITA Medical revenue growth (NTM/LTM) is 45%. |
| What is the current EV/Revenue multiple of AVITA Medical? | Current revenue multiple of AVITA Medical is 2.1x. |
| Is AVITA Medical profitable? | Yes, AVITA Medical is EBITDA-positive (as of the last 12 months). |
| What is the current EBITDA of AVITA Medical? | AVITA Medical's last 12 months EBITDA is -$39.3M. |
| What is AVITA Medical's EBITDA margin? | AVITA Medical's last 12 months EBITDA margin is -50%. |
| What is the current EV/EBITDA multiple of AVITA Medical? | Current EBITDA multiple of AVITA Medical is -4.2x. |
| What is the current FCF of AVITA Medical? | AVITA Medical's last 12 months FCF is -$37.2M. |
| What is AVITA Medical's FCF margin? | AVITA Medical's last 12 months FCF margin is -48%. |
| What is the current EV/FCF multiple of AVITA Medical? | Current FCF multiple of AVITA Medical is -4.5x. |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
